Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: Preliminary findings of a phase II, single-arm study.

被引：0
|
作者：
Xu, Xiaojing
Yu, Yiyi
Wang, Yan
Cui, Yuehong
Li, Wei
Liang, Li
Li, Qian
Yu, Shan
Feng, Yi
Liu, Qing
Zhang, Pengfei
Lv, Minzhi
Liu, Tianshu
机构：
[1] Fudan Univ, Dept Oncol, Canc Ctr, Zhongshan Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Biostat, Canc Ctr, Shanghai, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3566
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial
    Nakamura, Masato
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings
    Saleh, Mansoor
    Cassier, Philippe A.
    Eberst, Lauriane
    Naik, Gurudatta
    Morris, Van K.
    Pant, Shubham
    Terret, Catherine
    Gao, Ling
    Long, Amanda
    Mao, Huzhang
    McNeely, Samuel
    Wagner, Erin K.
    Carlesi, Roberto M.
    Fu, Siqing
    ONCOLOGIST, 2020, 25 (11): : E1628 - E1639
  • [33] Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).
    Shitara, Kohei
    Yamazaki, Kentaro
    Uetake, Hiroyuki
    Kato, Takeshi
    Oki, Eiji
    Yamanaka, Takeharu
    Ohashl, Yasuo
    Yoshino, Takayukl
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
    Shitara, Kohei
    Yokota, Tomoya
    Takahari, Daisuke
    Shibata, Takashi
    Ura, Takashi
    Utsunomiya, Setsuo
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Najima, Mina
    Kawai, Hiroki
    Tajika, Masahiro
    Sawaki, Akira
    Yatabe, Yasushi
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (04) : 688 - 693
  • [35] Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
    Kohei Shitara
    Tomoya Yokota
    Daisuke Takahari
    Takashi Shibata
    Takashi Ura
    Setsuo Utsunomiya
    Yoshitaka Inaba
    Hidekazu Yamaura
    Yozo Sato
    Mina Najima
    Hiroki Kawai
    Masahiro Tajika
    Akira Sawaki
    Yasushi Yatabe
    Kei Muro
    Investigational New Drugs, 2011, 29 : 688 - 693
  • [36] A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401)
    Hironori Samura
    Eiji Oki
    Hiroshi Okumura
    Takefumi Yoshida
    Seiichiro Kai
    Kazuma Kobayashi
    Tatsuya Kinjo
    Shinichiro Mori
    Tetsuo Tohyama
    Kippei Ohgaki
    Hirofumi Kawanaka
    Akitaka Makiyama
    Norio Ureshino
    Masahito Kotaka
    Takayuki Shimose
    Koji Ando
    Hiroshi Saeki
    Hideo Baba
    Yoshihiko Maehara
    Masaki Mori
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 285 - 294
  • [37] Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Pre-treated Metastatic Colorectal Cancer Harboring Wild-type KRAS
    Shitara, Kohei
    Yokota, Tomoya
    Takahari, Daisuke
    Shibata, Takashi
    Ura, Takashi
    Komatsu, Yoshito
    Yuki, Satoshi
    Yoshida, Motoki
    Takiuchi, Hiroya
    Utsunomiya, Setsuo
    Yatabe, Yasushi
    Muro, Kei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (07) : 699 - 701
  • [38] A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401)
    Samura, Hironori
    Oki, Eiji
    Okumura, Hiroshi
    Yoshida, Takefumi
    Kai, Seiichiro
    Kobayashi, Kazuma
    Kinjo, Tatsuya
    Mori, Shinichiro
    Tohyama, Tetsuo
    Ohgaki, Kippei
    Kawanaka, Hirofumi
    Makiyama, Akitaka
    Ureshino, Norio
    Kotaka, Masahito
    Shimose, Takayuki
    Ando, Koji
    Saeki, Hiroshi
    Baba, Hideo
    Maehara, Yoshihiko
    Mori, Masaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (02) : 285 - 294
  • [39] Cetuximab maintenance therapy in unresectable metastatic colorectal cancer patients with wild-type RAS and BRAF: A single-center retrospective study.
    Jiang, Tao
    Lin, Xiaoyan
    Chen, Hao
    Zhen, Jianwei
    Du, Bin
    Liu, Qing
    Zhong, Dongta
    Yang, Baoyu
    Wang, Xinli
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Dose finding phase Ib study of triplet plus cetuximab for patients with wild-type RAS gene metastatic colorectal cancer (TRICETSU study)
    Satake, H.
    Kotake, T.
    Okita, Y.
    Hatachi, Y.
    Yasui, H.
    Kotaka, M.
    Kato, T.
    Tsuji, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 69 - 69
12345